Literature DB >> 16919421

A unique role for striatal serotonergic systems in the withdrawal from adolescent nicotine administration.

Theodore A Slotkin1, Frederic J Seidler.   

Abstract

Adolescent smokers experience more severe withdrawal symptoms upon smoking cessation than do adults, even when daily smoking has occurred for only a short period or with low levels of consumption. Animal models of nicotine withdrawal indicate involvement of striatal serotonin (5-HT) systems in nicotine reward, withdrawal and craving. We evaluated indices of striatal 5-HT and dopamine (DA) synaptic activity, neurotransmitter levels and turnover (metabolite/transmitter ratio), after continuous nicotine infusions to adolescent rats from postnatal days 30 to 47, using a dose rate (6 mg/kg/day) that produces plasma levels typical of smokers. Withdrawal was accompanied by a significant and persistent loss of striatal 5-HT synaptic activity, evidenced by an initial decline in turnover followed by a reduction in 5-HT content without a compensatory increase in turnover. Similar effects were seen for striatal DA activity. These effects were superimposed on a loss of stimulatory 5-HT cellular responses and promotion of inhibitory responses as identified in an earlier work with this model. None of these alterations was seen during withdrawal in adult rats given the same regimen. The unique adolescent withdrawal effects were not seen when the adolescent nicotine treatment period was shortened to early adolescence (days 30-37), even if the administration paradigm was changed to twice-daily injections to maximize withdrawal stress. Our results are consistent with unique effects of adolescent nicotine withdrawal on striatal 5-HT and DA systems, and point to a potential for serotonin-specific reuptake inhibitors as alternatives to nicotine replacement therapy for smoking cessation in adolescents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919421     DOI: 10.1016/j.ntt.2006.06.001

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  8 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

2.  Nicotine produces long-term increases in cocaine reinforcement in adolescent but not adult rats.

Authors:  Stephanie Collins Reed; Sari Izenwasser
Journal:  Brain Res       Date:  2016-07-30       Impact factor: 3.252

3.  Nicotine administration in adolescence reprograms the subsequent response to nicotine treatment and withdrawal in adulthood: sex-selective effects on cerebrocortical serotonergic function.

Authors:  Theodore A Slotkin; Jennifer Card; Frederic J Seidler
Journal:  Brain Res Bull       Date:  2014-01-30       Impact factor: 4.077

Review 4.  Mechanistic insights into nicotine withdrawal.

Authors:  Michael Paolini; Mariella De Biasi
Journal:  Biochem Pharmacol       Date:  2011-07-20       Impact factor: 5.858

Review 5.  Reward, addiction, withdrawal to nicotine.

Authors:  Mariella De Biasi; John A Dani
Journal:  Annu Rev Neurosci       Date:  2011       Impact factor: 12.449

Review 6.  The dynamic effects of nicotine on the developing brain.

Authors:  Jennifer B Dwyer; Susan C McQuown; Frances M Leslie
Journal:  Pharmacol Ther       Date:  2009-03-05       Impact factor: 12.310

Review 7.  Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.

Authors:  Xia Li; Svetlana Semenova; Manoranjan S D'Souza; Astrid K Stoker; Athina Markou
Journal:  Neuropharmacology       Date:  2013-06-07       Impact factor: 5.250

Review 8.  Neuroimaging is a novel tool to understand the impact of environmental chemicals on neurodevelopment.

Authors:  Megan K Horton; Amy E Margolis; Cheuk Tang; Robert Wright
Journal:  Curr Opin Pediatr       Date:  2014-04       Impact factor: 2.856

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.